Viatris NEW Zealand Pharmaceutical Import Profile — New Zealand (DGFT 2022–2026)

Name: Viatris NEW Zealand Pharmaceutical Import Records from India — 5 Products, $2.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Viatris NEW Zealand — Pharmaceutical Importer Profile (2026) | 5 Products, $2.3M Trade | TransData Nexus

Viatris NEW Zealand

Pharmaceutical Importer · New Zealand · Antibiotics Focus · $2.3M Total Trade · DGFT Verified

Viatris NEW Zealand is a pharmaceutical importer based in New Zealand with a total trade value of $2.3M across 5 products in 5 therapeutic categories. Based on 84 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Viatris NEW Zealand sources from 2 verified Indian suppliers, with Medreich Limited accounting for 98.6% of imports.

Viatris NEW Zealand — Import Portfolio & Supplier Network

Viatris NEW Zealand import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Viatris NEW Zealand?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$4.6M	200	98.6%
12/8 Saraswathi Ammal Street	$65.5K	5	1.4%

Viatris NEW Zealand sources from 2 verified Indian suppliers across 136 distinct formulations. The sourcing is highly concentrated — Medreich Limited accounts for 98.6% of total imports, indicating a strategic single-source relationship.

What Formulations Does Viatris NEW Zealand Import?

Formulation	Value	Ships
Amoxicillin capsules BP 500MG	$397.5K	9
Paracetamol 500MG+codeine phosphate 8MG	$275.6K	12
Erythromycin ethylsucccinate tablets	$200.0K	4
Ibuprofen tablets 200MG (relieve	$167.9K	4
Domperidone tablets 10MG (domperidone	$140.7K	3
Amoxicillin capsules BP 500MG	$100.0K	2
Amoxicillin capsules BP 500MG alphamox500 400506144 50x10s 5925	$100.0K	2
Erythromycin ethylsuccinate tablets	$100.0K	2
Amoxycillin for oral suspension	$84.0K	5
Ibuprofen tablets 200MG relieve ibuprofen 200MG 100x10s 5789	$67.7K	2
Amoxycillin for oral suspension 250MG/5ML (alphamox 250MG/5ML sf) 100ML (67132 packs	$64.5K	3
Erythromycin ethylsuccinate tablets 400MG (e-mycin) 100s (6744 packs)	$62.3K	3
Amoxycillin for oral suspension 250MG/5ML (alphamox 250MG/5ML sf) 100ML (54192 packs	$54.4K	3
Ibuprofen tablets 200MG (relieve	$50.0K	1
Amoxicillin capsules BP 500MG alphamox500 50x10s 6873	$50.0K	1

Viatris NEW Zealand imports 136 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Erythromycin	Antibiotics	$901.7K	33	1.1%	9
2	Codeine	Analgesics & Antipyretics	$869.6K	30	0.8%	8
3	Domperidone	Gastrointestinal	$348.9K	12	1.2%	11
4	Flucloxacillin	Advanced Antibiotics	$100.0K	2	0.3%	15
5	Brufen	Brand Names & OTC Products	$42.8K	7	1.0%	15

Viatris NEW Zealand imports 5 pharmaceutical products across 5 categories into New Zealand totaling $2.3M.

Viatris NEW Zealand — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Viatris New Zealand is a pharmaceutical importer and distributor operating within New Zealand's healthcare sector. As a subsidiary of Viatris Inc., a global healthcare company formed in 2020 through the merger of Mylan and Upjohn (a legacy division of Pfizer), Viatris New Zealand plays a pivotal role in ensuring the availability of high-quality, trusted medicines to the New Zealand market. (viatris.nz)

Headquartered in Auckland, Viatris New Zealand employs approximately 50 individuals from diverse backgrounds, including Asia, the Pacific, and Brazil. This diverse workforce underscores the company's commitment to leveraging global expertise to meet local healthcare needs. (viatrisconnect.co.nz) Viatris New Zealand's portfolio encompasses a broad range of therapeutic areas, with over 500 registered products, reflecting its significant presence in the country's pharmaceutical distribution landscape. (viatris.nz)

2Distribution Network

Viatris New Zealand's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the country. While specific warehouse locations are not publicly disclosed, the company operates a robust supply chain capable of delivering over one million units directly through its warehouse every month. (viatris.nz) This capacity indicates a well-established logistics framework that supports nationwide coverage. Additionally, Viatris New Zealand's affiliation with Viatris Inc., which has a global manufacturing network, including facilities in Australia, enhances its ability to source and distribute a diverse range of medicines. (viatrisconnect.co.nz)

3Industry Role

In New Zealand's pharmaceutical supply chain, Viatris New Zealand functions primarily as a wholesaler and distributor. The company imports a diverse array of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various international suppliers. This role is crucial in bridging the gap between global manufacturers and local healthcare providers, ensuring that patients have access to a wide range of medications. Viatris New Zealand's operations are integral to the country's healthcare infrastructure, facilitating the availability of essential medicines across multiple therapeutic categories.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Viatris NEW Zealand

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Viatris New Zealand's sourcing strategy exhibits a high degree of concentration, with a significant majority of its pharmaceutical imports originating from a single supplier, MEDREICH LIMITED. This supplier accounts for $4.6 million in imports across 200 shipments, representing 98.6% of the total import value. Such a concentrated sourcing approach can offer benefits like streamlined logistics and potentially favorable pricing. However, it also introduces risks associated with supplier dependency, including potential disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by the supplier. The limited number of suppliers (two) and the dominance of MEDREICH LIMITED suggest that Viatris New Zealand's supply chain may be vulnerable to single-source risks.

2Supply Chain Resilience

The resilience of Viatris New Zealand's supply chain is closely tied to its reliance on MEDREICH LIMITED for the majority of its pharmaceutical imports. The absence of additional backup suppliers for key products indicates a potential vulnerability in the event of supply disruptions. The diversity of formulations imported (136 unique formulations) suggests a broad product range; however, the heavy reliance on a single supplier for these products may limit the company's ability to quickly adapt to supply chain challenges. To enhance resilience, Viatris New Zealand could consider diversifying its supplier base and establishing relationships with multiple suppliers to mitigate risks associated with single-source dependency.

Importing Pharmaceuticals into New Zealand — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for New Zealand

1Regulatory Authority & Framework

In New Zealand, the Medicines and Medical Devices Safety Authority (Medsafe) is the primary regulatory body responsible for the regulation of therapeutic products, including pharmaceuticals. Medsafe operates under the Medicines Act 1981 and the Misuse of Drugs Act 1975, which govern the importation, manufacture, and distribution of medicines within the country. The regulatory framework ensures that all medicines meet safety, efficacy, and quality standards before they are approved for use in New Zealand. For Indian pharmaceutical companies seeking to export to New Zealand, obtaining marketing authorization from Medsafe is a critical step in the regulatory process.

2Import Licensing & GMP

Import licensing in New Zealand is managed by Medsafe, which requires that all imported medicines be accompanied by appropriate documentation, including a Certificate of Pharmaceutical Product (CPP) issued by the regulatory authority of the exporting country. This certificate attests to the product's compliance with the regulatory standards of the exporting country. Good Manufacturing Practice (GMP) certification is also essential; New Zealand recognizes GMP certifications from authorities such as the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian pharmaceutical manufacturers seeking to export to New Zealand must ensure that their facilities are GMP-compliant and that their products are accompanied by the necessary import licenses and certifications.

Viatris NEW Zealand — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Viatris New Zealand's product strategy focuses on importing a diverse range of pharmaceutical formulations across multiple therapeutic categories, including antibiotics, analgesics, antipyretics, and gastrointestinal medications. This approach aligns with the company's mission to provide high-quality, trusted medicines to New Zealanders, addressing a broad spectrum of healthcare needs. The market demand for these products is driven by the prevalence of various health conditions in the population, necessitating a steady supply of effective treatments. By importing a wide array of products, Viatris New Zealand ensures that healthcare providers have access to essential medications, thereby supporting better health outcomes for patients.

2Sourcing Profile

Viatris New Zealand's sourcing strategy emphasizes the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from international suppliers. This approach allows the company to offer a comprehensive product portfolio without the complexities associated with manufacturing raw active pharmaceutical ingredients (APIs). India plays a significant role in Viatris New Zealand's procurement strategy, serving as a key source of high-quality, cost-effective finished formulations. By leveraging India's manufacturing capabilities, Viatris New Zealand can provide a diverse range of medicines to meet the needs of the New Zealand market.

Market Positioning

Seller's Guide — How to Become a Supplier to Viatris NEW Zealand

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Viatris New Zealand's supply chain. The company's current sourcing pattern, characterized by a high degree of concentration with a single supplier, indicates potential gaps that new suppliers can fill. By offering reliable and consistent supply options, Indian exporters can position themselves as valuable partners, enhancing their competitiveness in the New Zealand market. To capitalize on this opportunity, Indian suppliers should ensure compliance with New Zealand's regulatory requirements, including GMP certification and appropriate labeling standards.

2Requirements & Qualifications

Indian exporters seeking to supply Viatris New Zealand must ensure that their

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Viatris NEW Zealand

What products does Viatris NEW Zealand import from India?

Viatris NEW Zealand imports 5 pharmaceutical products across 5 categories. Top imports: Erythromycin ($901.7K), Codeine ($869.6K), Domperidone ($348.9K), Flucloxacillin ($100.0K), Brufen ($42.8K).

Who supplies pharmaceuticals to Viatris NEW Zealand from India?

Viatris NEW Zealand sources from 2 verified Indian suppliers. The primary supplier is Medreich Limited (98.6% of imports, $4.6M).

What is Viatris NEW Zealand's total pharmaceutical import value?

Viatris NEW Zealand's total pharmaceutical import value from India is $2.3M, based on 84 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Viatris NEW Zealand focus on?

Viatris NEW Zealand imports across 5 categories. The largest: Antibiotics (39.8%), Analgesics & Antipyretics (38.4%), Gastrointestinal (15.4%).

Get Full Viatris NEW Zealand Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.